Patents by Inventor Johji Inazawa
Johji Inazawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
FLUORESCENCE IMAGE ANALYSIS METHOD, FLUORESCENCE IMAGE ANALYZER, FLUORESCENCE IMAGE ANALYSIS PROGRAM
Publication number: 20230058796Abstract: A fluorescence image analyzer has an imaging unit for capturing a first image containing at least a part of a region of a cell as an imaging target for a plurality of cells in a sample in which a target site on a chromosome is labeled with a fluorescent dye, and a second image including fluorescence generated from a fluorescent dye labeling the target site of the cell of the first image. The processing unit selects a plurality of test cells having specific morphological characteristics to be tested from a plurality of cells based on at least the first image, and extracts the bright spots of fluorescence generated from the fluorescent dye. The processing unit identifies cells with chromosomal abnormalities and/or cells without chromosomal abnormalities based on the extracted bright spots, and generates information related to the ratio of cells with chromosomal abnormalities relative to the test cells.Type: ApplicationFiled: August 17, 2022Publication date: February 23, 2023Applicants: National University Corporation Tokyo Medical and Dental University, Kyoto Prefectural Public University Corporation, SYSMEX CORPORATIONInventors: Johji INAZAWA, Junya KURODA, Masaki KINOSHITA -
Patent number: 10876115Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.Type: GrantFiled: January 7, 2019Date of Patent: December 29, 2020Assignee: National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki
-
Publication number: 20190367915Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.Type: ApplicationFiled: January 7, 2019Publication date: December 5, 2019Applicant: National University Corporation Tokyo Medical and Dental UniversityInventors: Johji INAZAWA, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki
-
Patent number: 9994843Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.Type: GrantFiled: February 17, 2014Date of Patent: June 12, 2018Assignee: National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki
-
Publication number: 20160053257Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.Type: ApplicationFiled: February 17, 2014Publication date: February 25, 2016Applicant: National University Corporation Tokyo Medical and Dental UniversityInventors: Johji INAZAWA, Jun INOUE, Shinsuke YAMAMOTO, Tatsuyuki KAWANO, Ken-ichi KOZAKI
-
Patent number: 9229003Abstract: It is an object of the present invention to identify a gene that exhibits behavior which is characteristic of carcinomas such as thyroid carcinoma, so as to provide a method for detecting carcinoma and a cell growth suppressing agent. The present invention provides a method for detecting carcinoma, which comprises detecting malignant transformation by detecting at least one alteration of gene existing in chromosomal regions 1q41, 3q28, 7q31.2, 8p12, 8q22.2, 8q24.21, 11q4.1, 17q12, 20q11, 9p21.3, 16q13.2, and 16q23.1 in a specimen.Type: GrantFiled: July 15, 2009Date of Patent: January 5, 2016Assignees: FUJIFILM Corporation, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITYInventors: Johji Inazawa, Issei Imoto, Takaya Ishihara, Hitoshi Tsuda
-
Patent number: 9090942Abstract: An object of the present invention is to provide a method for detecting cancer and an agent for suppressing cell growth by identification of genes showing behaviors characteristic in cancer such as esophageal carcinoma. The present invention provides a method for detecting cancer, which comprises detecting canceration through detection of amplification of at least one gene existing in an 1q32-1q41 chromosomal region in a specimen.Type: GrantFiled: March 24, 2010Date of Patent: July 28, 2015Assignees: FUJIFILM Corporation, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITYInventors: Johji Inazawa, Issei Imoto, Shuhei Komatsu, Ken-ichi Kozaki, Hitoshi Tsuda
-
Patent number: 9034796Abstract: An analytical method aided with a nucleic acid microarray, the nucleic acid microarray having a spot (X 1) onto which a first probe nucleic acid is immobilized, the method includes: allowing a labeled sample nucleic acid (A 1) of a sample to be tested to hybridize with the first probe nucleic acid; providing the spot (X 1) with a labeled verification nucleic acid (B) that has a sequence capable of hybridizing with at least a part of the first probe nucleic acid and is labeled with a label different from the labeled sample nucleic acid (A 1), and allowing the labeled verification nucleic acid (B) to hybridize with at least the first probe nucleic acid at all spots; measuring a labeled quantity value (F 1) of the labeled sample nucleic acid (A 1); and measuring a labeled quantity value (Fc 1) of the labeled verification nucleic acid (B).Type: GrantFiled: May 27, 2009Date of Patent: May 19, 2015Assignees: FUJIFILM Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Dai Ujihara, Hideyuki Kanehara, Johji Inazawa, Issei Imoto
-
Methods for evaluating the stage of ovarian cancer or the survival rate of an ovarian cancer patient
Patent number: 8741641Abstract: An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 2q14. 2, 3p24. 1, 3q26. 2, 3q29, 4q34. 2, 6q23, 9p21. 3, 11q13. 3, 13q22.1, 13q33. 1, 13q33. 3, 15q12, 15q15. 1, 17p12, 17p13. 1, 17p13. 3, 18q21. 1, 18q21. 2, 18q21. 31, 18q21. 32, 18q21. 33, 18q23, 20q13. 13, 20q13. 2, 20q13. 31, 20q13. 33, Xp11. 23, Xp13.1, Xp13. 3, Xp26. 2, Xp26. 3, or Xq28 in the specimen.Type: GrantFiled: October 24, 2012Date of Patent: June 3, 2014Assignees: FUJIFILM Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Issei Imoto, Ryoko Kikuchi -
Publication number: 20140018248Abstract: An object of the present invention is to provide a method for detecting cancer and an agent for suppressing cell growth by identification of genes showing behaviors characteristic in cancer such as esophageal carcinoma. The present invention provides a method for detecting cancer, which comprises detecting canceration through detection of amplification of at least one gene existing in an 1q32-1q41 chromosomal region in a specimen.Type: ApplicationFiled: March 24, 2010Publication date: January 16, 2014Inventors: Johji INAZAWA, Issei Imoto, Shuhei Komatsu, Ken-ichi Kozaki, Hitoshi Tsuda
-
Methods for evaluating the stage of ovarian cancer or the survival rate of an ovarian cancer patient
Patent number: 8318431Abstract: An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 2q14. 2, 3p24. 1, 3q26. 2, 3q29, 4q34. 2, 6q23, 9p21. 3, 11q13. 3, 13q22.1, 13q33. 1, 13q33. 3, 15q12, 15q15. 1, 17p12, 17p13. 1, 17p13. 3, 18q21. 1, 18q21. 2, 18q21. 31, 18q21. 32, 18q21. 33, 18q23, 20q13. 13, 20q13. 2, 20q13. 31, 20q13. 33, Xp11. 23, Xp13.1, Xp13. 3, Xp26. 2, Xp26. 3, or Xq28 in the specimen.Type: GrantFiled: May 28, 2008Date of Patent: November 27, 2012Assignees: Fujifilm Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Issei Imoto, Ryoko Kikuchi -
Patent number: 8216785Abstract: The present invention is intended to provide a means for judging the malignancy of neuroblastoma and the progress of spontaneous regression thereof. The present invention provides a method for detecting cancer which comprises detecting activation or inactivation of the lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) gene and amplification of the MYCN gene in a specimens to evaluate the malignancy of the specimens and the progress of spontaneous regression.Type: GrantFiled: September 28, 2009Date of Patent: July 10, 2012Assignees: Fujifilm Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Issei Imoto, Jun Inoue
-
Patent number: 8183223Abstract: The present invention is directed to methods for suppressing the growth of oral squamous-cell carcinoma cells. The methods include introducing at least one gene selected from miR-137 or miR-193a into oral squamous-cell carcinoma cells.Type: GrantFiled: December 9, 2010Date of Patent: May 22, 2012Assignees: Fujifilm Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Ken-ichi Kozaki, Issei Imoto
-
Patent number: 8143003Abstract: It is an object to be achieved by the present invention to provide a method for detecting cancer and a cell growth inhibiting agent by the identification of genes exhibiting characteristic behavior in cancers such as oral squamous-cell carcinoma. The present invention provides a method for detecting cancer, which comprises detecting at least one gene alteration existing in chromosomal region 4q35 in a specimen.Type: GrantFiled: April 27, 2009Date of Patent: March 27, 2012Assignees: Fujifilm Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Johji Inazawa, Issei Imoto, Erina Nakamura, Hitoshi Tsuda
-
Publication number: 20110207626Abstract: An object the present invention is to analyze human chromosomes in terms of the presence of a duplication or deletion so as to determine the cause of a multiple congenital anomaly syndrome accompanying mental retardation, to thereby provide a method for determining whether or not a human subject has the syndrome. The present invention includes detecting a hemizygote deletion in the region 10q24.31-10q25.1 of a human chromosome of a human subject, to thereby determine whether or not the subject has a multiple congenital anomaly syndrome accompanying mental retardation. The detection is preferably carried out by hybridizing a reference nucleic acid fragment including a part of the 10q24.31-10q25.1 region with a nucleic acid fragment of a specimen, and detecting a signal attributed to the hemizygote deletion of the 10q24.31-10q25.1 region.Type: ApplicationFiled: July 30, 2009Publication date: August 25, 2011Applicant: FUJIFILM CORPORATIONInventors: Johji Inazawa, Issei Imoto, Shin Hayashi, Yoshinori Aizu
-
Publication number: 20110105357Abstract: An analytical method aided with a nucleic acid microarray, the nucleic acid microarray having a spot (X 1) onto which a first probe nucleic acid is immobilized, the method includes: allowing a labeled sample nucleic acid (A 1) of a sample to be tested to hybridize with the first probe nucleic acid; providing the spot (X 1) with a labeled verification nucleic acid (B) that has a sequence capable of hybridizing with at least a part of the first probe nucleic acid and is labeled with a label different from the labeled sample nucleic acid (A 1), and allowing the labeled verification nucleic acid (B) to hybridize with at least the first probe nucleic acid at all spots; measuring a labeled quantity value (F 1) of the labeled sample nucleic acid (A 1); and measuring a labeled quantity value (Fc 1) of the labeled verification nucleic acid (B).Type: ApplicationFiled: May 27, 2009Publication date: May 5, 2011Applicant: FUJIFILM CORPORATIONInventors: Dai Ujihara, Hideyuki Kanehara, Johji Inazawa, Issei Imoto
-
Publication number: 20110076768Abstract: An object of the present invention is to identify genes exhibiting characteristic behavior in the cases of carcinoma such as oral squamous-cell carcinoma using a change of expression level of micro RNA in oral squamous-cell carcinoma as an indicator, so as to provide a method for detecting carcinoma and an agent for suppressing carcinoma. The present invention A method for detecting oral squamous-cell carcinoma, which comprises detecting malignant transformation of specimens by employing a change of expression level of micro RNA as an indicator, and an agent for suppressing oral squamous-cell carcinoma using micro RNA.Type: ApplicationFiled: December 9, 2010Publication date: March 31, 2011Inventors: Johji INAZAWA, Ken-ichi Kozaki, Issei Imoto
-
Patent number: 7867709Abstract: An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as anaplastic thyroid cancer. The present invention provides a method for detecting cancer which comprises detecting canceration of a specimen using the amplification of a gene of the p12 region of chromosome 8 in the specimen as an indicator.Type: GrantFiled: March 21, 2007Date of Patent: January 11, 2011Assignees: Fujifilm Corporation, Tokyo Medical and Dental UniversityInventors: Wei Yu, Johji Inazawa, Issei Imoto
-
Publication number: 20100304997Abstract: A method carries out a nucleic acid analysis using a nucleic acid microarray. A probe nucleic acid including a probe sequence (a?) complementary to a target sequence (a) and a sequence (b?) which is different from the probe sequence (a?) is immobilized on the nucleic acid microarray. The method includes hybridizing the nucleic acid microarray and a labeled abnormality detecting nucleic acid (B) containing a sequence (b) which can be bound to the sequence (b?), obtaining a labeled amount value (Fc1) of the labeled abnormality detecting nucleic acid (B) from a spot (X1), and determining, based on the measured labeled amount value (Fc1), as to whether or not the spot (X1) is an abnormal spot unsuitable for detecting the target nucleic acid.Type: ApplicationFiled: May 26, 2010Publication date: December 2, 2010Applicants: FUJIFILM Corporation, National University Corporation Tokyo Medical and Dental UniversityInventors: Junya Yoshida, Hideyuki Kanehara, Dai Ujihara, Johji Inazawa, Issei Imoto
-
Publication number: 20100105868Abstract: The present invention is intended to provide a means for judging the malignancy of neuroblastoma and the progress of spontaneous regression thereof. The present invention provides a method for detecting cancer which comprises detecting activation or inactivation of the lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) gene and amplification of the MYCN gene in a specimens to evaluate the malignancy of the specimens and the progress of spontaneous regression.Type: ApplicationFiled: September 28, 2009Publication date: April 29, 2010Inventors: Johji Inazawa, Issei Imoto, Jun Inoue